Revolution Medicines Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib

Revolution Medicines (RVMD) has received a "Safe to Proceed" letter from the FDA for its drug candidate Daraxonrasib, indicating regulatory approval to advance its development.